首页> 外文期刊>Pigment cell & melanoma research >Enhancing the evaluation of PI3K inhibitors through 3Dmelanoma models
【24h】

Enhancing the evaluation of PI3K inhibitors through 3Dmelanoma models

机译:通过3D黑色素瘤模型加强PI3K抑制剂的评估

获取原文
获取原文并翻译 | 示例
       

摘要

Targeted therapies for mutant BRAF metastatic melanoma are effective but not curative due to acquisition of resistance. PI3K signaling is a common mediator of therapy resistance in melanoma; thus, the need for effective PI3K inhibitors is critical. However, testing PI3K inhibitors in adherent cultures is not always reflective of their potential invivo. To emphasize this, we compared PI3K inhibitors of different specificity in two- and three-dimensional (2D, 3D) melanoma models and show that drug response predictions gain from evaluation using 3D models. Our results in 3D demonstrate the anti-invasive potential of PI3K inhibitors and that drugs such as PX-866 have beneficial activity in physiological models alone and when combined with BRAF inhibition. These assays finally help highlight pathway effectors that could be involved in drug response in different environments (e.g. p4E-BP1). Our findings show the advantages of 3D melanoma models to enhance our understanding of PI3K inhibitors.
机译:突变BRAF转移性黑色素瘤的靶向治疗有效,但由于获得耐药性而无法治愈。 PI3K信号传导是黑色素瘤治疗耐药性的常见介体。因此,对有效PI3K抑制剂的需求至关重要。但是,在贴壁培养物中测试PI3K抑制剂并不总是能反映其潜在的体内作用。为了强调这一点,我们在二维和三维(2D,3D)黑色素瘤模型中比较了不同特异性的PI3K抑制剂,并表明通过使用3D模型进行评估可获得药物反应预测。我们在3D中的结果证明了PI3K抑制剂的抗侵袭潜力,并且药物(例如PX-866)在单独的生理模型中以及与BRAF抑制结合时均具有有益的活性。这些分析最终有助于突出可能在不同环境中参与药物反应的通路效应子(例如p4E-BP1)。我们的发现显示了3D黑色素瘤模型在增强我们对PI3K抑制剂的了解方面的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号